首次无诱因静脉血栓栓塞延长口服抗凝期间复发风险的长期系统评价与荟萃分析
BACKGROUND: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain.…
要点
- 延长抗凝期间复发VTE发生率为1.41/100人年,5年累积发生率7.1%。
- 直接口服抗凝药复发VTE发生率1.08/100人年,维生素K拮抗剂为1.55/100人年。
- 复发VTE病死率为4.9%,致命性肺栓塞5年累积发生率1.2%。
核心结论
- 首次无诱因VTE患者延长抗凝期间长期复发风险低但不可忽略。
- 临床医生和患者应知晓该风险,疑似复发VTE时及时处理。
- 该估计值可用于告知患者延长抗凝期间的预期风险,并评估延长治疗的净临床获益。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE和Cochrane CENTRAL。
- 纳入报告首次无诱因VTE患者完成≥3个月初始治疗后额外抗凝至少6个月期间复发VTE的随机试验和前瞻性队列研究。
- 使用研究层面发生率及随机效应荟萃分析合并结果。
主要发现
- 复发VTE发生率为1.41/100人年(95%CI 1.03-1.84),5年累积发生率7.1%(3.0%-13.2%)。
- 致命性肺栓塞发生率为0.09/100人年(95%CI 0.04-0.16),5年累积发生率1.2%(0.4%-4.6%)。
- 直接口服抗凝药复发VTE发生率为1.08/100人年(95%CI 0.77-1.44),维生素K拮抗剂为1.55/100人年(95%CI 1.01-2.20)。
- 复发VTE病死率为4.9%(95%CI 2.2%-8.7%)。
临床怎么用
- 可利用本研究的复发VTE和致命性肺栓塞发生率估计值,向患者说明延长抗凝期间的预期风险。
- 可结合复发VTE病死率4.9%评估延长抗凝的净临床获益,辅助长期管理决策。
- 疑似复发VTE时应及时采取适当处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain. OBJECTIVES: To determine the incidence of recurrent VTE during extended anticoagulation of up to 5 years in patients with a first unprovoked VTE. METHODS: MEDLINE, EMBASE, and the Cochrane CENTRAL were searched to identify randomized trials and prospective cohort studies reporting recurrent VTE among patients with a first unprovoked VTE who were to receive anticoagulation for a minimum of six additional months after completing ≥3 months of initial treatment. Unpublished data on number of recurrent VTE and person-years, obtained from authors of included studies, were used to calculate study-level incidence rate, and random-effects meta-analysis was used to pool results. RESULTS: Twenty-six studies and 15 603 patients were included in the analysis. During 11 631 person-years of follow-up, the incidence of recurrent VTE and fatal pulmonary embolism per 100 person-years was 1.41 (95% CI, 1.03-1.84) and 0.09 (0.04-0.16), with 5-year cumulative incidences of 7.1% (3.0%-13.2%) and 1.2% (0.4%-4.6%), respectively. The incidence of recurrent VTE was 1.08 (95% CI, 0.77-1.44) with direct oral anticoagulants and 1.55 (1.01-2.20) with vitamin K antagonists. The case-fatality rate of recurrent VTE was 4.9% (95% CI, 2.2%-8.7%). CONCLUSIONS: In patients with a first unprovoked VTE, the long-term risk of recurrent VTE during extended anticoagulation is low but not negligible. Thus, clinicians and patients should be aware of this risk and take appropriate and timely action in case of suspicion of recurrent VTE. Estimates from this study can be used to advise patients on what to expect while receiving extended anticoagulation, and estimate the net clinical benefit of extended treatment to guide long-term management of unprovoked VTE.
引用
- Khan F, Tritschler T, Kimpton M, et al. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021. PMID: 34379859. doi:10.1111/jth.15491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。